# US 2016/0355475 A1 · Novel indole derivative compound and pharmaceutical composition comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355475 A1
- Document ID: US20160355475A1
- Status: Published application
- Kind: A1
- Application number: 15/108,873
- Filed: 2015-01-02
- Published: 2016-12-08
- Earliest claimed: 2014-01-03
- Assignees: Chong Kun Dang Pharmaceutical Corp.
- Applicants: Chong Kun Dang Pharmaceutical Corp.
- Inventors: Changsik LEE; Hyun-Mo YANG; Dohoon KIM; Miseon BAE; Youngil CHOI; Nina HA
- Web page: https://patentgrep.com/patent/US20160355475A1

## CPC

- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/10: with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/08: linked by a carbon chain containing alicyclic rings
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a novel indole derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The compound according to the present invention can selectively inhibit histone deacetylase (HDAC), and thus can be used to effectively treat a disease associated with histone deacetylase (HDAC) activity.

## Claims

### Claim 1

An indole derivative compound represented by the following formula I, an isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof:
wherein
R1 is hydrogen, halogen, a straight or branched C1-5 alkyl, —NH2, —OH, a straight or branched chain C1-5 alkoxy, —CF3, aryl, a 4- to 6-membered heteroaryl containing one or two heteroatoms selected from N, O and S,
wherein the aryl and heteroaryl may each independently be unsubstituted or substituted with halogen, a straight or branched chain C1-5 alkoxy or a straight or branched chain C1-5 alkyl;
R2 is hydrogen, halogen, a straight or branched chain C1-5 alkyl, —NH2, —OH, a straight or branched chain C2-10 alkylalkoxy (—C1-5—O—C1-5 alkyl), a straight or branched chain C1-5 alkoxy, —CF3, a straight or branched C1-5 alkyl-halogen, or a straight or branched chain C1-5 alkyl hydroxide (—C1-5 alkyl-OH);
R3 and R4 are each independently hydrogen or —OH;
R5 is hydrogen, halogen, —CF3, or a straight or branched chain C1-3 alkyl;
n1 and n2 are each independently 0, 1 or 2;
A is
a 3- to 8-membered C2-12 heterocycloalkyl containing one or two heteroatoms selected from N, O and S, or a 3- to 8-membered C2-12 heteroaryl containing one or two heteroatoms selected from N, O and S, wherein Y is C or N, Z is C, O or N, R6 and R7 are each independently hydrogen, halogen, a straight or branched chain C1-5 alkyl, —NH2, —OH, a straight or branched chain C2-10 alkylalkoxy (—C1-5—O—C1-5 alkyl), a straight or branched chain C1-5 alkoxy, —CF3, a straight or branched chain C1-5 alkyl-halogen, or a straight or branched chain C1-5 alkyl hydroxide (—C1-5 alkyl-OH), and n3 and n4 are each independently 0, 1 or 2;
Xa, Xb1, Xb2, Xb3 and Xb4 are each independently C or N;
B and D are each independently —H, C or halogen, and when B and D are H or halogen, Ra, Rb, Rc, Rd or Re, linked to B and D, does not exist;
m is 0, 1 or 2;
Ra is hydrogen, halogen, a straight or branched chain C1-5 alkyl, a C3-12 cycloalkyl, phenyl, —OH, a 5- or 6-membered heteroaryl containing one or two heteroatoms selected from N and O, or ═O;
Rb does not exist or is hydrogen, halogen, a straight or branched chain C1-5 alkyl, —OH, a straight or branched chain C1-5 alkoxy, a C3-12 cycloalkyl, a 5- or 6-membered heteroaryl containing one or two heteroatoms selected from N and O, or phenyl;
the straight or branched chain C1-5 alkyl, C3-12 cycloalkyl and phenyl in Ra or Rb may each independently be unsubstituted or substituted with halogen, —CN, thiazole, a straight or branched chain C1-5 alkoxy or a straight or branched chain C1-5 alkyl;
Rc is —H, halogen, a straight or branched chain C1-5 alkyl, a straight or branched chain C1-5 alkoxy, —CO(O)C1-5 alkyl, aryl, a 4- to 6-membered heteroaryl containing one or two heteroatoms selected from N, O and S, a C3-12 cycloalkyl, —OH, or phenyl;
Rd is hydrogen, halogen, a straight or branched chain C1-5 alkyl, a straight or branched chain C1-5 alkoxy, a C3-12 cycloalkyl, —OH, or phenyl;
Rc and Rd may be linked together to form a C3-8 cycloalkyl or a 4- to 6-membered cycloheteroalkyl containing one or two heteroatoms selected from N, O and S;
Re is hydrogen, halogen, —CF3, a straight or branched chain C1-3 perfluoroalkyl, a straight or branched chain C1-5 alkyl, a straight or branched chain C1-5 alkoxy, a 4- to 6-membered heterocycloalkyl containing one or two heteroatoms selected from N, O and S, a C3-12 cycloalkyl, aryl, a 4- to 6-membered heteroaryl containing one or two heteroatoms selected from N, O and S, NH2, —OH, a straight or branched chain —NHC1-5 alkyl, —N-(straight or branched chain C1-5 alkyl)2, or an aryl substituted with a straight or branched chain C1-5 alkyl;
wherein the straight or branched chain C1-5 alkyl, C3-12 cycloalkyl, 4- to 6-membered cycloheteroalkyl containing one or two heteroatoms selected from N, O and S, aryl, and 4- to 6-membered heteroaryl containing one or two heteroatoms selected from N, O and S in Rc, Rd or Re, or the cycloalkyl or cycloheteroalkyl formed by linkage between Rc and Rd, may each independently be unsubstituted or substituted with halogen, —CF3, —CN, thiazole, a straight or branched chain C1-5 alkoxy, a straight or branched chain C1-5 alkyl, a straight or branched chain —C(═O)C1-5 alkyl, a straight or branched chain —C(═O)OC1-5 alkyl, a straight or branched chain —C(═O)OC1-5alkyl, a straight or branched chain —C(═O)NHC1-5alkyl, a straight or branched chain SO2C1-5 alkyl, —CF3

### Claim 2 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein A in formula I is

### Claim 3 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein R3 and R4 in formula I are each independently hydrogen.

### Claim 4 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein the halogen is —F.

### Claim 5 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein R1 in formula I is —H, methyl, ethyl, propyl, butyl, phenyl,
pyridinyl or pyrimidinyl, in which the phenyl, pyridinyl or pyrimidinyl is unsubstituted or substituted with one or two —F or —CF3 groups.

### Claim 6 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein B and D in formula I are each independently carbon (C).

### Claim 7 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein the cycloheteroalkyl formed by linkage between Rc and Rd is

### Claim 8 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein the compound represented by formula I is selected from the group consisting of the following compounds:
N-hydroxy-4-((2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-4-((2-methyl-1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-4-((2-(morpholinomethyl)-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-4-((1-(2-(4-isopropylpiperazin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-4-((1-(2-(4-(2-hydroxyethyl)piperazin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-4-((1-(2-(4-(2-methoxyethyl)piperazin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
(S)—N-hydroxy-4-((1-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
(S)—N-hydroxy-4-((1-(2-(2-(methoxymethyl)pyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-4-((2-methyl-1-(2-(2-methyl-1H-imadazol-1-yl)ethyl)-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-6-((2-methyl-1-(2-(4-methylpeperazin-1-yl)ethyl)-1H-indol-3-yl)methyl)nicotinamide;
N-hydroxy-6-((2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl)methyl)nocotinamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(2-(3-fluoropiperidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
(S)-4-((1-(2-(2-(fluoromethyl)pyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(2-(4-fluoropiperidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-benzylpiperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-butylpiperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-phenethylpiperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
3-fluoro-4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(2-(1-(2-fluoro-2-methylpropyl)piperidin-4-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(2-(4-(2-fluoro-2-methylpropyl)piperazin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(2-(1-(2-ethyl-2-fluorobutyl)piperidin-4-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((5-fluoro-1-((1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((4-fluoro-tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((4-fluoro-tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((1-(2-(3-(hydroxymethyl)pyrroldin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
(S)-4-((5-fluoro-1-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((5-fluoro-1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
(S)-4-((5-fluoro-1-(2-(3-fluoropyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((5-fluoro-1-(2-(4-fluoropiperidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(2-(3-(fluoromethyl)pyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
(S)—N-hydroxy-4-((1-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
(S)-4-((1-(2-(3-fluoropyrrolidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((1-(2-(3-(hydroxymethyl)piperidin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
4-((2-butyl-1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((1-((1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)methyl)-2-propyl-1H-indol-3-yl)methyl)benzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-propyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-(3-(thiazol-2-yl)benzyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
N-hydroxy-4-((1-((1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)benzamide;
4-((1-((1-((3-fluoroxetan-3-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
tert-butyl4-fluoro-4-((4-((3-(4-(hydroxycarbamoyl)benzyl)-2-methyl-1H-indol-1-yl)methyl)piperidin-1-yl)methyl)piperidine-1-carboxylate;
4-((1-((1-((4-fluoropiperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((1-acetyl-4-fluoropiperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((4-fluoro-1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((4-fluoro-1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-phenyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-(2,4,5-trifluorobenzyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
4-((1-((1-(2-fluorobenzyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-(pyridin-4-ylmethyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
4-((1-((1-(4-fluorobenzyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-(pyridin-2-ylmethyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-(pyridin-4-yl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-(pyrimidin-5-yl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((2-(3,5-difluorophenyl)-1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((2-(3,6-dihydro-2H-pyran-4-yl)-1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-(3-fluorobenzyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-(pyridin-3-ylmethyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
4-((1-(2-((3S,5R)-4-(2-fluoro-2-methylpropyl)-3,5-dimethylpiperazin-1-yl)ethyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(4-(4-(2-fluoro-2-methylpropyl)piperazin-1-yl)butyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-(3-(4-(2-fluoro-2-methylpropyl)piperazin-1-yl)propyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-((3-methyloxetan-3-yl)methyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
4-((1-((1-((4-fluoro-1-methylpiperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((4-fluoro-1-isopropylpiperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-fluoro-4-((4-((3-(4-(hydroxycarbamoyl)benzyl)-2-methyl-1H-indol-1-yl)methyl)piperidin-1-yl)methyl)-N-isopropylpiperidine-1-carboxamide;
4-((1-((1-((4-fluoro-1-(methylsulfonyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-(3,5-bis(trifluoromethyl)benzyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((1-fluorocyclohexyl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((4-fluoro-1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((6-fluoro-1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)pyrrolidin-3-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide;
N-hydroxy-4-((2-methyl-1-((1-((1-(trifluoromethyl)cyclobutyl)methyl)piperidin-4-yl)methyl)-1H-indol-3-yl)methyl)benzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)(hydroxy)methyl)-N-hydroxybenzamide;
4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-hydroxybenzamide;
4-((1-((1-((3-fluorooxetan-3-yl)methyl)azetidin-3-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide; and
4-((1-((1-(2-fluoro-2-methylpropyl)azetidin-3-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide.

### Claim 9 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein the compound represented by formula I is 4-((1-((1-(2-fluoro-2-methylpropyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide.

### Claim 10 (depends on 1)

The compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, wherein the compound represented by formula I is 4-((1-((1-((3-fluorooxetan-3-yl)methyl)piperidin-4-yl)methyl)-2-methyl-1H-indol-3-yl)methyl)-N-hydroxybenzamide.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound represented by formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1, together with a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, which is for prevention or treatment of a disease associated with histone deacetylase (HDAC) activity.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the disease associated with histone deacetylase (HDAC) activity is cell proliferative disease, autosomal dominant disease, fibrosis, autoimmune disease, diabetes, acute neurological disease, chronic neurological disease, hypertrophy, congestive heart failure, amyotrophic lateral sclerosis, glaucoma, angiogenesis-related ocular disease, or Alzheimer's disease.

### Claim 14 (depends on 1)

A method for preventing or treating a disease associated with histone deacetylase (HDAC) activity, the method comprising administering, to mammals including humans, a composition comprising as an active ingredient a compound of formula I, isomer thereof, pharmaceutically acceptable salt thereof, or hydrate or solvate thereof according to claim 1.

### Claim 15

(canceled)
